Lunec J - Search Results

1

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.

Aptullahoglu E, Ciardullo C, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J. Aptullahoglu E, et al. Among authors: lunec j. Int J Mol Sci. 2023 Jan 26;24(3):2410. doi: 10.3390/ijms24032410. Int J Mol Sci. 2023. PMID: 36768733 Free PMC article.

2

Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines.

Lastowska M, Van Roy N, Bown N, Speleman F, Lunec J, Strachan T, Pearson AD, Jackson MS. Lastowska M, et al. Among authors: lunec j. Genes Chromosomes Cancer. 1998 Oct;23(2):116-22. doi: 10.1002/(sici)1098-2264(199810)23:2<116::aid-gcc4>3.0.co;2-5. Genes Chromosomes Cancer. 1998. PMID: 9739014

3

Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.

Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Tweddle DA, et al. Among authors: lunec j. Cancer Res. 2001 Jan 1;61(1):8-13. Cancer Res. 2001. PMID: 11196202

4

Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma.

Lastowska M, Van Roy N, Bown N, Speleman F, Roberts P, Lunec J, Strachan T, Pearson AD, Jackson MS. Lastowska M, et al. Among authors: lunec j. Med Pediatr Oncol. 2001 Jan;36(1):20-3. doi: 10.1002/1096-911X(20010101)36:1<20::AID-MPO1006>3.0.CO;2-E. Med Pediatr Oncol. 2001. PMID: 11464884

5

Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors.

Łastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson AD, Jackson MS. Łastowska M, et al. Among authors: lunec j. Genes Chromosomes Cancer. 2002 Aug;34(4):428-36. doi: 10.1002/gcc.10089. Genes Chromosomes Cancer. 2002. PMID: 12112532

6

The p53 pathway and its inactivation in neuroblastoma.

Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J. Tweddle DA, et al. Among authors: lunec j. Cancer Lett. 2003 Jul 18;197(1-2):93-8. doi: 10.1016/s0304-3835(03)00088-0. Cancer Lett. 2003. PMID: 12880966 Review.

7

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

Hardcastle IR, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Källblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J. Hardcastle IR, et al. Among authors: lunec j. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1515-20. doi: 10.1016/j.bmcl.2004.12.061. Bioorg Med Chem Lett. 2005. PMID: 15713419

8

Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene.

Liang H, Lunec J. Liang H, et al. Among authors: lunec j. Gene. 2005 Nov 21;361:112-8. doi: 10.1016/j.gene.2005.07.018. Epub 2005 Oct 3. Gene. 2005. PMID: 16202543

9

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.

Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, Tweddle DA. Carr J, et al. Among authors: lunec j. Cancer Res. 2006 Feb 15;66(4):2138-45. doi: 10.1158/0008-5472.CAN-05-2623. Cancer Res. 2006. PMID: 16489014

10

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.

Hardcastle IR, Ahmed SU, Atkins H, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Källblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J. Hardcastle IR, et al. Among authors: lunec j. J Med Chem. 2006 Oct 19;49(21):6209-21. doi: 10.1021/jm0601194. J Med Chem. 2006. PMID: 17034127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

335 results

Search Page